{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T02:43:31Z","timestamp":1711421011921},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2011,5,1]],"date-time":"2011-05-01T00:00:00Z","timestamp":1304208000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Urologe"],"published-print":{"date-parts":[[2011,5]]},"DOI":"10.1007\/s00120-011-2517-7","type":"journal-article","created":{"date-parts":[[2011,5,9]],"date-time":"2011-05-09T10:26:33Z","timestamp":1304936793000},"page":"609-620","source":"Crossref","is-referenced-by-count":5,"title":["Induratio penis plastica (IPP)"],"prefix":"10.1007","volume":"50","author":[{"given":"A.","family":"Hauptmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Diemer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Weidner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,5,11]]},"reference":[{"key":"2517_CR1","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.urology.2007.02.042","volume":"69","author":"Bennet","year":"2007","unstructured":"Bennet NE, Guhring P, Mulhall JP (2007) Intralesional verapamil prevents the progression of Peyronie\u2018s disease. J Urol 69:1181\u20131184","journal-title":"J Urol"},{"key":"2517_CR2","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/ncpuro0409","volume":"3","author":"Brant","year":"2006","unstructured":"Brant WO, Dean RC, Lue TF (2006) Treatment of Peyronie\u2018s disease with oral pentoxifylline. Nat Clin Pract Urol 3:111\u2013115","journal-title":"Nat Clin Pract Urol"},{"key":"2517_CR3","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1046\/j.1464-410X.2002.02738.x","volume":"89","author":"Cavallini","year":"2002","unstructured":"Cavallini G, Biagiotti G, Koverech A, Vitali G (2002) Oral propionyl-l-carnitine and intraplaque verapamil in the therapy of advanced and resistant Peyronie\u2018s disease. BJU Int 89:895\u2013900","journal-title":"BJU Int"},{"key":"2517_CR4","first-page":"165","volume":"70","author":"Cipollone","year":"1998","unstructured":"Cipollone G, Nicolai M, Mastroprimiano G et al (1998) Betamethason versus placebo in Peyronie\u2018s disease. Arch Ital Urol Androl 70:165\u2013168","journal-title":"Arch Ital Urol Androl"},{"key":"2517_CR5","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/0090-4295(85)90285-7","volume":"25","author":"Essed","year":"1985","unstructured":"Essed E, Schroeder F (1985) New surgical treatment for Peyronie\u2018s disease. Urology 25:582\u2013587","journal-title":"Urology"},{"key":"2517_CR6","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1743-6109.2006.00417.x","volume":"4","author":"Fitch","year":"2007","unstructured":"Fitch WP 3rd, Easterling WJ, Talbert RL (2007) Topical verapamil HCL, topical trifluopromazine and topical magnesium sulfate for the treatment of Peyronie\u2018s disease \u2013 a placebo controlled pilot study. J Sex Med 4:477\u2013484","journal-title":"J Sex Med"},{"key":"2517_CR7","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrurol.2010.24","volume":"7","author":"Gonzales-Cadavid","year":"2010","unstructured":"Gonzales-Cadavid NF, Rajfer J (2010) Treatment of Peyronie\u2018s disease with PDE5 inhibitors: an antifibrotic strategy. Nat Rev Urol 7(4):215\u2013221","journal-title":"Nat Rev Urol"},{"key":"2517_CR8","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.juro.2006.10.065","volume":"177","author":"Greenfield","year":"2007","unstructured":"Greenfield JM, Shah SJ, Levine LA (2007) Verapamil verus saline in electromotive drug administration for Peyronie\u2018s disease: a double-blind, placebo controlled trial. J Urol 177:972\u2013975","journal-title":"J Urol"},{"key":"2517_CR9","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.eururo.2006.02.059","volume":"49","author":"Hauck","year":"2006","unstructured":"Hauck EW, Diemer TH, Schmelz HU, Weidner W (2006) A critical analysis of nonsurgical treatment of Peyronie\u2018s disease. Eur Urol 49:987\u2013997","journal-title":"Eur Urol"},{"key":"2517_CR10","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1016\/S0140-6736(00)05119-9","volume":"357","author":"Hauck","year":"2001","unstructured":"Hauck EW, Weidner W (2001) Fran\u00e7ois de la Peyronie and the disease named after him. Lancet 357:2049\u20132051","journal-title":"Lancet"},{"key":"2517_CR11","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/S1569-9056(11)61035-X","volume":"10","author":"Hauptmann","year":"2011","unstructured":"Hauptmann A, Diemer T, Weidner W (2011) Reconstructive penile surgery with small-incision corporoplasty and grafting followed by a postoperative penile rehabilitation program in Peyronie\u2018s disease. Europ Urol Suppl 10:326 A 1055","journal-title":"Europ Urol Suppl"},{"key":"2517_CR12","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/S0022-5347(06)00517-9","volume":"176","author":"Hellstrom","year":"2006","unstructured":"Hellstrom WJG, Kendirci M, Matern R et al (2006) Single-blind, multicenter, placebo controlled, parallel study to assess the safety and efficacy of intralesional interferon-alpha2b for minimally invasive treatment for Peyronie\u2018s disease. J Urol 176:394\u2013398","journal-title":"J Urol"},{"key":"2517_CR13","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1743-6109.2007.00651.x","volume":"5","author":"Jordan","year":"2008","unstructured":"Jordan GH (2008) The use of intralesional clostridial collagenase injection therapy for Peyronie\u2018s disease: a prospective, single-center, non-placebo-controlled study. J Sex Med 5:180\u2013187","journal-title":"J Sex Med"},{"key":"2517_CR14","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/j.1743-6109.2007.00461.x","volume":"4","author":"Kadioglu","year":"2007","unstructured":"Kadioglu A, Sanli O, Akman T et al (2007) Graft materials in Peyronie\u2018s disease surgery: a comprehenisve review. J Sex Med 4:581\u2013595","journal-title":"J Sex Med"},{"key":"2517_CR15","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/sj.ijir.3900519","volume":"12","author":"Kadioglu","year":"2000","unstructured":"Kadioglu A, Tefekli A, K\u00f6ksal T et al (2000) Treatment of Peyronie\u2018s disease with oral colchicine: long-term results and predictive parameters of successful outcome. Int J Impot Res 12:169\u2013175","journal-title":"Int J Impot Res"},{"key":"2517_CR16","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1743-6109.2004.10104.x","volume":"1","author":"Lue","year":"2004","unstructured":"Lue TF, Giuliano F, Montorsi F et al (2004) Summary of recommendations on sexual dysfunctions in men. J Sex Med 1:6\u201323","journal-title":"J Sex Med"},{"key":"2517_CR17","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1111\/j.1743-6109.2009.01250.x","volume":"6","author":"Moreno","year":"2009","unstructured":"Moreno SA, Morgentaler A (2009) Testosterone deficiency and Peyronie\u2018s disease: pilot data suggesting a significant relationship. J Sex Med 6:1729-1735","journal-title":"J Sex Med"},{"key":"2517_CR18","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1097\/01.ju.0000127744.18878.f1","volume":"171","author":"Mulhall","year":"2004","unstructured":"Mulhall JP, Creech SD, Boorjian SA et al (2004) Subjective and objective analysis of the prevalence of Peyronie\u2018s disease in a population of men presenting for prostate cancer screening. J Urol 171:2350\u20132353","journal-title":"J Urol"},{"key":"2517_CR19","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0022-5347(06)00270-9","volume":"175","author":"Mulhall","year":"2006","unstructured":"Mulhall JP, Schiff J, Guhring P (2006) An analysis of the natural history of Peyronie\u2018s disease. J Urol 175:2115\u20132118","journal-title":"J Urol"},{"key":"2517_CR20","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0022-5347(17)63751-0","volume":"93","author":"Nesbit","year":"1965","unstructured":"Nesbit R (1965) Congenital curvature of the phallus: report of three cases with description of corrective operation. J Urol 93:230\u2013232","journal-title":"J Urol"},{"key":"2517_CR21","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.eururo.2009.05.012","volume":"56","author":"Palmieri","year":"2009","unstructured":"Palmieri A, Imbimbo C, Longo N et al (2009) A first prospective, randomised, double-blind, placebo-controlled clinical trial evaluating extracorporeal shock wave therapy for the treatment of Peyronie\u2018s disease. Eur Urol 56:363-370","journal-title":"Eur Urol"},{"key":"2517_CR22","first-page":"41","volume":"9","author":"Pryor","year":"1983","unstructured":"Pryor JP, Farell CR (1983) Controlled clinical trial of vitamine E in Peyronie\u2018s disease. Prog Reprod Biol Med 9:41\u201345","journal-title":"Prog Reprod Biol Med"},{"key":"2517_CR23","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1111\/j.1743-6109.2010.01781.x","volume":"7","author":"Ralph","year":"2010","unstructured":"Ralph D, Gonzalez-Cadavid N, Mirone V et al (2010) The management of Peyronie\u2018s disease. Evidence-based 2010 Guidelines. J Sex Med 7:2359\u20132374","journal-title":"J Sex Med"},{"key":"2517_CR24","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1111\/j.1464-410X.1992.tb15836.x","volume":"70","author":"Ralph","year":"1992","unstructured":"Ralph DJ, Brooks MD, Botazzo GF, Pryor JP (1992) The treatment of Peyronie\u2018s disease with tamoxifen. Br J Urol 70:648-651","journal-title":"Br J Urol"},{"key":"2517_CR25","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1464-410X.2009.09041.x","volume":"106","author":"Safarinejad","year":"2010","unstructured":"Safarinejad MR, Asgari MA, Hosseini SY, Dadkhah F (2010) A double-blind, placebo-controlled study of the efficacy and safety of pentoxifylline in early chronic Peyronie\u2018s disease. BJU Int 106:240\u2013248","journal-title":"BJU Int"},{"key":"2517_CR26","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/sj.ijir.3901185","volume":"16","author":"Safarinejad","year":"2004","unstructured":"Safarinejad MR (2004) Therapeutic effects of colchicine in the management of Peyronies\u2018s disease: a randomized double-blind, placebo-controlled study. Int J Impot Res 16:238\u2013243","journal-title":"Int J Impot Res"},{"key":"2517_CR27","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.juro.2007.05.162","volume":"178","author":"Safarinejad","year":"2007","unstructured":"Safarinejad MR, Hosseini SY, Kolahi AA (2007) Comparison of vitamin E and propionyl-L-carnitine with early chronic Peyronie\u2018s disease: a double-blind, placebo controlled, randomized study. J Urol 178:1398\u20131403","journal-title":"J Urol"},{"key":"2517_CR28","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1016\/S0022-5347(05)68087-1","volume":"162","author":"Teloken","year":"1999","unstructured":"Teloken C, Rhoden EL, Grazziotin TM et al (1999) Tamoxifen vs. placebo in the treatment of Peyronie\u2018s diesase. J Urol 162:2003\u20132005","journal-title":"J Urol"},{"key":"2517_CR29","unstructured":"Oxford Centre for Evidence-based Medicine - Levels of Evidence (March 2009) Produced by Bob Phillips, Chris Ball, Dave Sackett, Doug Badenoch, Sharon Straus, Brian Haynes, Martin Dawes since November 1998. Updated by Jeremy Howick March 2009. http:\/\/www.cebm.net\/index.aspx?o=1025"},{"key":"2517_CR30","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1111\/j.1743-6109.2009.01214.x","volume":"6","author":"Vardi","year":"2009","unstructured":"Vardi Y, Levine LA, Chen J et al (2009) Is there a place for conservative treatment in Peyronie\u2018s disease? J Sex Med 6:903\u2013909","journal-title":"J Sex Med"},{"key":"2517_CR31","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.eururo.2004.12.022","volume":"47","author":"Weidner","year":"2005","unstructured":"Weidner W, Hauck EW, Schnitker J (2005) Potassium paraaminobenzoate (POTABA\u00ae) in the treatment of Peyronie\u2018s disease: a prospective, placebo-controlled randomized study. Eur Urol 47:530\u2013536","journal-title":"Eur Urol"},{"key":"2517_CR32","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/S0022-5347(17)32519-3","volume":"152","author":"Wilson","year":"1994","unstructured":"Wilson SK, Delk 2nd JR (1994) A new treatment of Peyronie\u2018s disease: modeling the penis over an inflatable penile prothesis. J Urol 152:1121\u20131123","journal-title":"J Urol"},{"key":"2517_CR33","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/sj.ijir.3900997","volume":"15","author":"Wiltink","year":"2003","unstructured":"Wiltink J, Hauck EW, Ph\u00e4doyanon M et al (2003) Validation of the German version of the IIEF in patients with erectile dysfunction, Peyronie\u2018s disease and controls. Int J Imp Res 15:192\u2013197","journal-title":"Int J Imp Res"},{"key":"2517_CR34","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/01.ju.0000132144.71458.86","volume":"172","author":"Zargooshi","year":"2004","unstructured":"Zargooshi J (2004) Trauma as a cause of Peyronie\u2018s disease: penile fracture as a model of trauma. J Urol 172:186\u2013188","journal-title":"J Urol"}],"container-title":["Der Urologe"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-011-2517-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00120-011-2517-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-011-2517-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,10]],"date-time":"2019-06-10T16:47:33Z","timestamp":1560185253000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00120-011-2517-7"}},"subtitle":["Diagnostik und Therapie"],"short-title":[],"issued":{"date-parts":[[2011,5]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,5]]}},"alternative-id":["2517"],"URL":"https:\/\/doi.org\/10.1007\/s00120-011-2517-7","relation":{},"ISSN":["0340-2592","1433-0563"],"issn-type":[{"value":"0340-2592","type":"print"},{"value":"1433-0563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,5]]}}}